Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Purines and neuroprotection.

Trevor W Stone1

  • 1Division of Neuroscienec and Biomedical Systems, West Medical Bldg, University of Glasgow, Glasgow G12 8QQ, UK.

Advances in Experimental Medicine and Biology
|February 11, 2003
PubMed
Summary

Adenosine A2A receptor antagonists show promise for preventing neuronal damage, offering neuroprotection without significant side effects. These compounds may provide a new therapeutic avenue for conditions like stroke, unlike previous NMDA receptor antagonists.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential regulation of kynurenine pathway metabolism by the galantamine-memantine combination in rheumatologic diseases: A hypothesis-driven review.

The Journal of pharmacology and experimental therapeutics·2026
Same author

Paradoxical Expression of Ionotropic Glutamate Receptors in Leucocytes.

Clinical reviews in allergy & immunology·2026
Same author

The Contribution of Paresis, Age, and the Effect of Short Training on Cognitive-Motor Dual-Task Interference After Stroke: A Pilot Study.

Life (Basel, Switzerland)·2025
Same author

Memantine for the Treatment of Primary Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Controlled Trials.

Clinical drug investigation·2025
Same author

Galantamine-Memantine Combination in the Treatment of Parkinson's Disease Dementia.

Brain sciences·2025
Same author

The Complex World of Kynurenic Acid: Reflections on Biological Issues and Therapeutic Strategy.

International journal of molecular sciences·2024

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neuroprotection

Background:

  • Adenosine receptors (A1, A2A, A3) play a role in protecting neurons from various insults, including mechanical, hypoxic/ischemic, and excitotoxic damage.
  • A1 receptor activation offers neuroprotection but is limited by side effects; A2A and A3 receptors also show protective potential.
  • Previous therapeutic approaches, such as NMDA receptor antagonists, have shown limited success in clinical trials for stroke.

Purpose of the Study:

  • To investigate the neuroprotective potential of adenosine receptor modulation, focusing on A2A receptor antagonists.
  • To evaluate the therapeutic viability of A2A receptor antagonists in preventing neuronal death.
  • To compare the potential clinical utility of A2A receptor antagonists with other neuroprotective strategies.

Main Methods:

  • Review of studies on adenosine receptor activation and antagonism in neuronal protection models.
  • Examination of selective A2A receptor antagonists, including ZM 241385 and SCH 58261.
  • Assessment of A2A receptor antagonist efficacy against ischemia, excitotoxicity, and combined insults.

Main Results:

  • A2A receptor activation can protect neurons, though the precise mechanism (central vs. peripheral) requires further clarification.
  • Selective A2A receptor antagonists demonstrated neuroprotection against ischemia and excitotoxicity.
  • A2A receptor antagonists reduced neuronal damage induced by excitotoxins and free radicals, with potential for minimal side effects due to lack of activation by endogenous adenosine.

Conclusions:

  • A2A receptor antagonists represent promising therapeutic candidates for preventing neuronal damage, offering a potential alternative to less successful treatments.
  • The potential for minimal side effects makes A2A receptor antagonists particularly attractive for clinical application in neurodegenerative conditions and stroke.
  • Further research into adenosine A3 receptor agonists also suggests potential for chronic neuroprotection.

Related Experiment Videos